89bio, Inc. - Common Stock (ETNB)
Frequently Asked Questions About 89bio, Inc. - Common Stock (ETNB)
How can investors learn more about 89bio, Inc.?
Investors interested in learning more about 89bio, Inc. can visit the company's official website, where they can find information about its clinical pipeline, corporate governance, financial performance, and press releases. Additionally, investors can access financial reports, attend investor conferences, and engage with investor relations representatives for further insights into the company's operations and outlook.
How does 89bio, Inc. ensure its research is innovative?
89bio, Inc. ensures its research is innovative by focusing on cutting-edge science and technologies, collaborating with industry experts, and continuously reviewing emerging data in liver and metabolic disease research. The company emphasizes a rigorous R&D process that fosters creativity and exploration of novel therapies while adhering to scientific integrity and regulatory requirements.
How does 89bio, Inc. measure its success?
89bio, Inc. measures its success through key performance indicators such as the progress of clinical trials, the advancement of its product pipeline, securing funding, and achieving regulatory milestones. The company also evaluates its impact through patient outcomes and feedback, striving to create value for shareholders while improving the quality of care for patients in need.
How does 89bio, Inc. prioritize patient needs?
89bio, Inc. prioritizes patient needs by conducting thorough market research and engaging with the patient community to understand their experiences and challenges. The company seeks to develop therapies that address existing treatment gaps and improve patient outcomes, ensuring that the development process is aligned with the needs and expectations of those living with liver and metabolic diseases.
Is 89bio, Inc. involved in any partnerships?
89bio, Inc. actively seeks partnerships and collaborations to enhance its research capabilities and accelerate drug development. The company may collaborate with academic institutions, research organizations, and other biopharmaceutical companies to leverage additional expertise, share resources, and expand its operational capabilities in pursuit of effective therapies.
What are the clinical trials in which 89bio is involved?
89bio, Inc. is conducting various clinical trials primarily focused on the evaluation of EGF-001 and its efficacy in treating NASH and related metabolic disorders. These trials assess the safety, pharmacokinetics, and overall impact of the drug on liver function, helping to establish its viability as a treatment option for patients. The company aims to progress through stages of clinical development, seeking to address regulatory requirements for potential market approval.
What challenges does 89bio, Inc. face?
89bio, Inc. faces several challenges, including the competitive nature of the biopharmaceutical industry, regulatory hurdles in drug development, and the inherent uncertainties of clinical trials. Additionally, market acceptance of new therapies and the need for funding to support ongoing research are ongoing challenges that the company must navigate as it works toward its goals.
What does 89bio, Inc. do?
89bio, Inc. is a biopharmaceutical company focused on developing innovative treatments for liver and metabolic diseases. The company's lead product candidate, EGF-001, is aimed at treating nonalcoholic steatohepatitis (NASH) and exploring various formulations to optimize therapeutic efficacy. By leveraging advanced science and clinical development strategies, 89bio is dedicated to bringing meaningful therapies to patients with unmet medical needs.
What financial backing does 89bio, Inc. have?
89bio, Inc. has secured funding from a combination of private investors and public market offerings, enabling the company to finance its research and development activities. The company's access to capital is crucial for advancing its clinical trials and sustaining its operations as it seeks to bring its novel therapies to market.
What is NASH?
Nonalcoholic steatohepatitis (NASH) is a severe form of fatty liver disease that occurs in people who drink little or no alcohol. It is marked by liver inflammation and damage, which can lead to liver fibrosis, cirrhosis, and ultimately liver failure. NASH is part of a broader spectrum of liver diseases associated with metabolic disorders, and effective treatment options are limited, highlighting the significant unmet medical need in this area.
What is the lead product candidate of 89bio?
The lead product candidate of 89bio, Inc. is EGF-001, which is a therapeutic designed to target nonalcoholic steatohepatitis (NASH). EGF-001 aims to address the underlying causes of this disease by reducing liver fat and inflammation, with the goal of improving liver function and overall health outcomes for affected patients.
What is the stock symbol for 89bio, Inc.?
The stock symbol for 89bio, Inc. is ETNB, and it is traded on the Nasdaq stock exchange. This allows investors to buy and sell shares of the company, providing a way for the public to participate in the financial growth and success of the company as it advances its clinical pipelines.
What is the vision of 89bio, Inc.?
The vision of 89bio, Inc. is to improve the lives of patients with liver and metabolic diseases by developing innovative and effective therapies. The company is committed to scientific excellence and patient-centric solutions, aiming to fulfill the unmet medical needs within these disease states while adhering to the highest standards of quality and compliance in drug development.
What milestones has 89bio, Inc. achieved?
89bio, Inc. has achieved several key milestones including the initiation of clinical trials for EGF-001 and completing preliminary studies that demonstrate the potential efficacy and safety of its product candidates. These milestones help validate the company’s approach and lay the groundwork for future advancements toward regulatory submissions and potential market entry.
What therapeutic areas does 89bio, Inc. focus on?
89bio, Inc. primarily focuses on therapeutic areas related to liver diseases and metabolic disorders, particularly nonalcoholic fatty liver disease (NAFLD) and its more severe form, NASH. The company aims to address the challenges associated with these conditions by developing medicines that can meaningfully impact patient health and improve quality of life.
When was 89bio, Inc. founded?
89bio, Inc. was founded in 2018. The company was established with the vision of developing impactful therapies for patients suffering from liver and metabolic diseases, marking its commitment to addressing significant healthcare challenges through its innovative research and drug development efforts.
Where is 89bio, Inc. headquartered?
89bio, Inc. is headquartered in San Francisco, California. This strategic location allows the company to be at the heart of a vibrant biotech ecosystem, facilitating collaboration with other innovators, access to expertise, and potential partnerships that can enhance its development pipeline.
Who are the key people in 89bio, Inc.?
The leadership team at 89bio, Inc. consists of highly experienced professionals in the biopharmaceutical industry, including executives with extensive backgrounds in drug development, clinical research, and business strategy. Key members typically include the CEO, COO, CFO, and heads of research and development, who together guide the company's mission to innovate and advance healthcare solutions.
What is the current price of 89bio, Inc. - Common Stock?
The current price of 89bio, Inc. - Common Stock is 7.190
When was 89bio, Inc. - Common Stock last traded?
The last trade of 89bio, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of 89bio, Inc. - Common Stock?
The market capitalization of 89bio, Inc. - Common Stock is 542.71M
How many shares of 89bio, Inc. - Common Stock are outstanding?
89bio, Inc. - Common Stock has 75.48M shares outstanding.